Publications

Publications

Filter Results: (29) Arrow Down

Show Results For

Page 1 of 29 Results →
  • October 2012
  • Teaching Plan

Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)

By: Robert F. Higgins
This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates... View Details
Keywords: Venture Philanthropy; Biotechnology; Funding Philanthropy Venture; Cystic Fibrosis; Foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Philanthropy and Charitable Giving; Science-Based Business; Nonprofit Organizations; Pharmaceutical Industry; Biotechnology Industry; United States; San Diego
Related
  • April 2009 (Revised October 2010)
  • Case

Bob Beall at the Cystic Fibrosis Foundation

By: Robert Steven Kaplan and Sophie Hood
Bob Beall is the Chief Executive Officer of the Cystic Fibrosis Foundation (CFF). CFF is an extremely successful organization, but Beall has to determine how to manage the organization through the financial crisis of 2008-2009. In this situation, donations are likely... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Philanthropy and Charitable Giving; Governing and Advisory Boards; Leadership; Crisis Management; Nonprofit Organizations
Related
  • March 2010 (Revised June 2011)
  • Teaching Note

Bob Beall at the Cystic Fibrosis Foundation (TN)

By: Robert Steven Kaplan
Teaching Note for 409107. View Details
Keywords: Health Industry
Related
  • October 2007 (Revised July 2013)
  • Case

Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech

By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details
Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Biotechnology Industry; Pharmaceutical Industry; San Diego
Related
  • February 2025
  • Article

Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States

By: Emma Brady, Ryan C. Perkins, Kate Cullen, Gregory S. Sawicki, Robert S. Kaplan and Gerardine Doyle
Lead clinicians at two large pediatric cystic fibrosis (CF) centers in the United States and Ireland measured and compared their ambulatory care costs. The clinicians selected three strata of patients (0–11 months, 1–5 years, and 6–17 years of age). Process maps were... View Details
Keywords: Health Care and Treatment; Cost; Service Delivery; Resource Allocation; Health Industry
Related
  • 01 Nov 2013
  • HBS Seminar

Eric Olson, Chief Scientific Officer at Syros Pharmaceuticals

  • November 2023 (Revised April 2024)
  • Case

BiomX: Bringing Phage Back to the Stage

By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Pharmaceutical Industry
Related
  • 30 Mar 2012
  • HBS Seminar

Matthew W. Emmens, Executive Chairman,Vertex Pharmaceuticals

  • 01 Jan 2005
  • News

Joseph J. O'Donnell, MBA 1971

programs. However, when the first of his three children, Joey, was born with cystic fibrosis in 1974, O'Donnell knew he would soon have to move into the private sector. The initial medical bill alone, after... View Details
  • Web

Health Care - Faculty & Research

Delivery." Health Services Research 60, no. 1 (February 2025). Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the... View Details
  • 01 Dec 2023
  • News

Wide Horizon

There were three critical events that led John Rodakis (MBA 1997) to form the nonprofit N of One in 2014 and ultimately dedicate his life to surfacing breakthrough autism research. The first occurred on Thanksgiving of 2012. He had driven about four hours with his wife... View Details
Keywords: Dan Morrell; Photos by Sarah Wilson
  • 24 Apr 2014
  • News

Finding a cure so that others may benefit

In 1986, Joe O’Donnell (AB 1967, MBA 1971) and his wife, Kathy, founded the Joey Fund in memory of their son, who died as a result of cystic fibrosis. O’Donnell has raised millions to battle the disease, and when asked to help the View Details
  • 01 Jun 2012
  • News

The Power of Philanthropy

When their son Joey died of cystic fibrosis in 1986 at age 12, Kathy and Joe O’Donnell (MBA 1971) vowed to fight the disease. O’Donnell, at the time the president of the Boston Concessions Group, joined with... View Details
Keywords: Health, Social Assistance; Religious, Grantmaking, Civic, Professional, and Similar Organizations; Personal Services
  • 31 May 2023
  • News

Alumni Achievement Awards 2023

came to Vertex in 2017, there was a medicine finishing early clinical trials with the potential to serve up to 90 percent of patients with cystic fibrosis (CF). In October 2019 that became Trikafta. Now CF... View Details
Keywords: leadership; management; work-life balance
  • 18 May 2020
  • News

Joe O’Donnell Named Harvard Medal Recipient

Campaign, which launched in 2013. The Gazette also notes his philanthropic efforts, which have been focused on cystic fibrosis research through the Joey Fund, which O’Donnell established in 1986 after losing... View Details
  • 05 Jun 2006
  • Research & Ideas

Using Competition to Reform Healthcare

a disadvantage. Strategic focus is not about narrow specialization, but the pursuit of excellence and deepening penetration in the chosen fields. At Fairview-University Children's Hospital (Minnesota), for example, a long-term commitment to excellence in the area of... View Details
Keywords: by Michael E. Porter; Health
  • 28 Jun 2010
  • HBS Case

Cincinnati Children’s Hospital Medical Center

implementing a "forcing function" into the operating room process that keeps patients out of the OR until they've received antibiotics, thus reducing surgical site infections. For another project, she selects the hospital's View Details
Keywords: by Julia Hanna; Health
  • 01 Jun 2010
  • News

Get Well Soon

implementing a “forcing function” into the operating room process that keeps patients out of the OR until they’ve received antibiotics, thus reducing surgical site infections. For another project, she selects the hospital’s Cystic View Details
Keywords: Julia Hanna; Ambulatory Health Care Services; Health, Social Assistance
  • Web

Kraft Accelerator

Investing Harvard Business Publishing Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech Harvard Business Publishing Learn how, and why, we got our start HEAR... View Details
  • 04 Sep 2019
  • News

Accelerating Scientific Discovery

development of a course that could enhance decision making by providing participants with the knowledge and skills to better manage, fund, and commercialize scientific discoveries that could potentially cure illnesses ranging from Alzheimer’s to View Details
Keywords: Jennifer Gillespie